UroGen Pharma (FRA:UR8) FFO


FRA:UR8 UroGen Pharma Ltd FRA:UR8
70 GF Score
Price €29.77
GF Value €16.47
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is UroGen Pharma FFO?

FFO (Funds from operations) only applies to REITs.

FRA:UR8
70GF Score
UroGen Pharma Ltd FRA:UR8
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is UroGen Pharma (FRA:UR8) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of €29.77 is trading 80.8% above its estimated GF Value™ of €16.47. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for FRA:UR8:

  • FFO:
  • GF Value™: €16.47 vs. price of €29.77 (80.8% above fair value)
  • GF Score™: 70/100 with 9 warning signs

No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


UroGen Pharma Business Description

Other Exchanges URGN:USA0XOD:UK
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
70GF Score

Get the complete analysis for FRA:UR8

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.77
Price
€16.47
GF Value